The Role of RSV in Functional Decline and Healthcare Dependency in Hospitalized Adults
The Role of RSV in Functional Decline and Healthcare Dependency in Hospitalized Adults supports researchers studying hospitalized adults in Italy to improve understanding of RSV’s wider effects and post-discharge care.
Funder: Pfizer Inc.
Due Dates: October 19, 2026 (submission deadline)
Funding Amounts: Up to EUR 150,000 per project for up to 18 months; EUR 300,000 total available
Summary: Supports independent research on the functional and non-respiratory effects of RSV in adults hospitalized in Italy.
Key Information: Both the principal investigator and applying institution must be based in Italy.
Description
Pfizer’s competitive research grant program seeks real-world evidence on how RSV-related hospitalization affects adults in Italy beyond acute respiratory illness. It supports independent projects using routinely collected hospital data to study functional decline, loss of independence, cardiovascular complications, and continuing healthcare dependency, particularly among older adults and people with chronic cardiovascular or pulmonary disease.
Projects may examine patients’ baseline vulnerability, complications and functional stress during hospitalization, and post-discharge outcomes such as readmissions, emergency department visits, or discharge to rehabilitation or long-term care. The findings are intended to improve risk stratification, targeted prevention, and post-discharge care. An expert review panel makes grant decisions.
